- Home
- BMEA vs DMO Comparison
BMEA vs DMO Comparison
Compare BMEA & DMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMEA
- DMO
- Stock Information
- Founded
- BMEA 2017
- DMO 2009
- Country
- BMEA United States
- DMO United States
- Employees
- BMEA N/A
- DMO N/A
- Industry
- BMEA Biotechnology: Pharmaceutical Preparations
- DMO Trusts Except Educational Religious and Charitable
- Sector
- BMEA Health Care
- DMO Finance
- Exchange
- BMEA Nasdaq
- DMO Nasdaq
- Market Cap
- BMEA 125.0M
- DMO 135.9M
- IPO Year
- BMEA 2021
- DMO N/A
- Fundamental
- Price
- BMEA $2.15
- DMO $11.75
- Analyst Decision
- BMEA Strong Buy
- DMO
- Analyst Count
- BMEA 8
- DMO 0
- Target Price
- BMEA $10.63
- DMO N/A
- AVG Volume (30 Days)
- BMEA 658.3K
- DMO 49.6K
- Earning Date
- BMEA 10-28-2025
- DMO 01-01-0001
- Dividend Yield
- BMEA N/A
- DMO 12.06%
- EPS Growth
- BMEA N/A
- DMO N/A
- EPS
- BMEA N/A
- DMO N/A
- Revenue
- BMEA N/A
- DMO N/A
- Revenue This Year
- BMEA N/A
- DMO N/A
- Revenue Next Year
- BMEA N/A
- DMO N/A
- P/E Ratio
- BMEA N/A
- DMO N/A
- Revenue Growth
- BMEA N/A
- DMO N/A
- 52 Week Low
- BMEA $1.29
- DMO $10.00
- 52 Week High
- BMEA $13.07
- DMO $11.80
- Technical
- Relative Strength Index (RSI)
- BMEA 61.18
- DMO 41.58
- Support Level
- BMEA $1.98
- DMO $11.66
- Resistance Level
- BMEA $2.18
- DMO $11.88
- Average True Range (ATR)
- BMEA 0.12
- DMO 0.10
- MACD
- BMEA 0.01
- DMO -0.02
- Stochastic Oscillator
- BMEA 75.76
- DMO 20.00
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.
About DMO Western Asset Mortgage Opportunity Fund Inc.
Western Asset Mortgage Defined Opportunity Fund Inc is a non-diversified, limited-term, closed-end management investment company. The fund's primary investment objective is to provide current income. As a secondary investment objective, the Fund will seek capital appreciation. The Fund seeks to achieve its investment objectives by investing in a diverse portfolio of mortgage-backed securities, consisting of non-agency residential mortgage-backed securities and commercial mortgage-backed securities.